A number of other research analysts also recently issued reports on ALNY. Jefferies Group restated a buy rating and set a $80.00 price target (down previously from $119.00) on shares of Alnylam Pharmaceuticals in a report on Wednesday, June 8th. FBR & Co restated a buy rating on shares of Alnylam Pharmaceuticals in a report on Friday, June 10th. Needham & Company LLC restated a buy rating on shares of Alnylam Pharmaceuticals in a report on Monday, June 13th. Cowen and Company restated a buy rating on shares of Alnylam Pharmaceuticals in a report on Sunday, June 12th. Finally, Leerink Swann restated a buy rating on shares of Alnylam Pharmaceuticals in a report on Sunday, June 12th. Eight investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The stock has a consensus rating of Buy and an average price target of $85.75.
Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) traded down 4.681% during mid-day trading on Thursday, hitting $34.515. The stock had a trading volume of 2,825,076 shares. Alnylam Pharmaceuticals has a 52-week low of $34.18 and a 52-week high of $110.75. The firm’s market cap is $2.96 billion. The stock’s 50-day moving average price is $71.81 and its 200-day moving average price is $66.25.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($1.05) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.24) by $0.19. The firm had revenue of $8.70 million for the quarter, compared to the consensus estimate of $8.09 million. Alnylam Pharmaceuticals had a negative return on equity of 29.60% and a negative net margin of 1,204.91%. The company’s quarterly revenue was up .2% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.85) earnings per share. On average, analysts anticipate that Alnylam Pharmaceuticals will post ($4.68) earnings per share for the current fiscal year.
In other news, CEO John Maraganore sold 30,151 shares of the business’s stock in a transaction that occurred on Wednesday, July 20th. The stock was sold at an average price of $64.69, for a total value of $1,950,468.19. Following the sale, the chief executive officer now directly owns 148,465 shares of the company’s stock, valued at approximately $9,604,200.85. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 4.00% of the stock is owned by insiders.
Several hedge funds have recently modified their holdings of the company. Nisa Investment Advisors LLC bought a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth approximately $128,000. Janney Montgomery Scott LLC bought a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth approximately $223,000. Seven Eight Capital LLC boosted its position in Alnylam Pharmaceuticals by 200.0% in the first quarter. Seven Eight Capital LLC now owns 2,700 shares of the biopharmaceutical company’s stock valued at $169,000 after buying an additional 1,800 shares during the period. Meeder Asset Management Inc. acquired a new position in Alnylam Pharmaceuticals during the second quarter valued at about $175,000. Finally, BlueMountain Capital Management LLC boosted its position in Alnylam Pharmaceuticals by 89.3% in the first quarter. BlueMountain Capital Management LLC now owns 3,179 shares of the biopharmaceutical company’s stock valued at $200,000 after buying an additional 1,500 shares during the period. 85.96% of the stock is currently owned by hedge funds and other institutional investors.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.